Editor-in-Chief Emeritus Pick of Papers
Free access for our readers
For each issue of Radiotherapy and Oncology, the Editor-in-Chief Emeritus Jens Overgaard, picks his favourite papers.
- Myeloablative Total Body Irradiation (TBI) has long been a cornerstone of the conditioning for hematopoietic stem cell transplantation (HSCT) in children , but is associated with considerable late effects [2–6]. Currently, use of TBI is mainly indicated in allogeneic HSCT for high-risk hematologic malignancy [7–13]. Fractionated TBI (fTBI) is standard for pediatric radiotherapy centers, but practices vary [14,15]. While most centers perform conventional TBI, several institutions have introduced highly conformal TBI techniques or Total Marrow Irradiation (TMI), Total Lymphoid Irradiation (TLI), and Total Marrow and Lymphoid Irradiation (TMLI) [16–19].
- Breast-conserving surgery (BCS) and adjuvant whole breast irradiation (WBI) has become the standard-therapy for early-stage breast cancer with equivalent overall survival and local control rates compared to mastectomy [1–3]. For further improvement of local control in younger patients or patients with high-risk tumors, an additional boost irradiation to the former tumor bed is recommended, which is usually delivered sequentially . However, with techniques like intensity-modulated radiotherapy (IMRT) a simultaneously integrated boost (SIB) may be applied.
- To evaluate outcome in patients with base of skull meningiomas treated with modern high precision radiation therapy (RT) techniques.
- To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal tissue complication probability (NTCP) of IMRT dose painting using 68Ga-HBED-CC PSMA PET/CT for target delineation in prostate cancer (PCa).
- To assess the utility of functional lung avoidance using IMRT informed by four-dimensional (4D) ventilation/perfusion (V/Q) PET/CT.
- To determine if acute symptoms during definitive radiotherapy (RT) or chemoradiation (CHRT) are prognostic factors for late dysphagia in head and neck cancer (HNC).